Tumor models to investigate the therapeutic efficiency of immunomodulators.

E. Talmadge, B. F. Lenz, M. S. Collins, K. A. Uithoven, M. A. Schneider, J. S. Adams, J. W. Pearson, W. J. Agee, R. E. Fox, R. K. Oldham

Research output: Contribution to journalArticlepeer-review

12 Scopus citations


The development of successful approaches to immunotherapy is dependent on the proper consideration of the pathobiology of metastasis and a better understanding of the principles of biological response modification. Immunomodulation as a therapeutic modality has not proven notably effective in animals with preexistent palpable disease, an observation in agreement with the results from clinical protocols. Therefore, rather than developing experimental immunotherapy models of immunoprophylaxis or models with minimal tumor burden, we believe it more appropriate to develop models based on preexistent metastatic disease in a tumor-conditioned host. The most rigorous test of a biological response modifier's efficiency prior to clinical trials will be provided from immunotherapeutic trials of palpable autochthonous tumors.

Original languageEnglish (US)
Pages (from-to)219-229
Number of pages11
JournalBehring Institute Mitteilungen
Issue number74
StatePublished - May 1984
Externally publishedYes

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Fingerprint Dive into the research topics of 'Tumor models to investigate the therapeutic efficiency of immunomodulators.'. Together they form a unique fingerprint.

Cite this